Cocaine Dependence
Conditions
Keywords
cocaine, treatment, progesterone
Brief summary
The purpose of this pilot treatment trial is to evaluate the efficacy of oral micronized PROG in cocaine-dependent women. Since we have shown (Evans & Foltin, 2006) that oral micronized PROG attenuates the positive subjective effects of smoked cocaine in females, but not in males, and we have preliminary data indicating that oral micronized PROG also reduces smoked cocaine self-administration in the laboratory, PROG appears to be an ideal potential candidate medication to evaluate in cocaine-dependent women. Prior to randomization to treatment, women will reside inpatient for one week to ensure cocaine abstinence since one of the primary outcome measures will be time to cocaine relapse.
Detailed description
Primary Aims: The primary aims will be directed at treatment efficacy. Relatively unique to cocaine treatment trials, one of the principal outcome measures will be time to cocaine relapse. We hypothesize that maintenance on PROG will increase the time to cocaine relapse compared to maintenance on placebo (PBO). Another cocaine-related efficacy endpoint will be the proportion of patients who achieve at least 2 consecutive weeks of cocaine abstinence (based on urine toxicology results) during the double-blind treatment phase. Lastly, the proportion of cocaine-negative urines collected throughout the treatment trial will be measured. We hypothesize that women in the PROG group will show a greater reduction in cocaine use compared to those in the PBO group. Secondary Aims: 1) Determine if response to laboratory stressors will predict treatment outcome. We hypothesize that those women with the greatest stress response will do worse in treatment and that maintenance on PROG will reduce stress/anxiety and thereby improve treatment outcome. 2) Determine if treatment retention is better in the PROG group compared to the PBO group and determine if maintenance on PROG improves overall functioning compared to maintenance on PBO based on the Clinical Global Inventory (CGI). We hypothesize that women in the PROG group will have better treatment retention and improvement in CGI scores compared to women in the PBO group. Tertiary Aims: To conduct exploratory analyses to determine whether 1) trauma history is related to treatment outcomes and 2) improvements in treatment outcome measures are related to decreases in HIV high-risk behaviors.
Interventions
Oral micronized progesterone (up to 400 mg/day), suspended in olive oil
DRUGPlacebo
matched placebo
Sponsors
National Institute on Drug Abuse (NIDA)
New York State Psychiatric Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Women between the ages of 18-60 who meet criteria for current cocaine dependence (DSM-IV-TR). Volunteers may meet criteria for abuse or dependence on nicotine, marijuana or alcohol, as long as the dependence is secondary to cocaine dependence and does not require any medical intervention (see additional exclusions for alcohol dependence below). 2\. Use cocaine by the smoked or intranasal route at least four days in the past month, with at least weekly cocaine use. 3\. Women with regular menstrual cycles (24-45 days) who are not pregnant, based on the results of a blood pregnancy test drawn at the time of screening. They must agree to use a barrier method of contraception with proven efficacy and agree not to become pregnant during the study. To confirm this, urine pregnancy tests will be conducted weekly. 4\. Women must be capable of giving informed consent and capable of complying with study procedures.
Exclusion criteria
* 1\. Meets DSM-IV-TR criteria for bipolar disorder, Schizophrenia, or any psychotic disorder other than transient psychosis due to drug abuse. 2\. Individuals with any current Axis I psychiatric disorder as defined by DSM-IV-TR supported by the SCID-I/P that in the investigator's judgment are unstable or would be disrupted by study medication. Disorders that are stable on psychotherapy or pharmacotherapy will not be exclusionary. Individuals will be permitted to take prescribed zolpidem and zaleplon or other medications for insomnia if there is no evidence of dependence on these substances. 3\. Individuals with current major depressive disorder. 4\. Individuals physiologically dependent on any other drugs (excluding nicotine or cannabis) that require medical intervention will be excluded and referred for treatment. Individuals with severe alcohol dependence , even without physiological dependence, or with any known alcohol-related diseases will also be excluded. 5\. Females who have any of the following medical contraindications: undiagnosed abnormal genital bleeding, known or suspected history of breast or genital cancer, active deep vein thrombosis, pulmonary embolism, or history of these conditions, active or recent (within last year) arterial thromboembolic diseases (e.g., stroke, myocardial infarction), liver dysfunction. 6\. Females who are cognitively impaired or have a chronic organic mental disorder. 7\. Individuals with current suicidal risk. 8\. Individuals with coronary vascular disease as indicated by history or suspected by abnormal ECG or history of cardiac symptoms. 9\. Unstable physical disorders which might make participation hazardous such as uncontrolled hypertension (Blood pressure \> 150/ 90, or Heart Rate \> 100 when sitting quietly), acute hepatitis (patients with chronic mildly elevated transaminases \< 3x upper limit of normal are acceptable), or uncontrolled diabetes. 10\. Individuals with a history of seizures. 11\. Women who are pregnant or nursing. 12\. Individuals who are legally mandated (e.g., to avoid incarceration, monetary or other penalties, etc.) to participate in substance abuse treatment program. 13\. Females with a known or suspected hypersensitivity to oral micronized progesterone.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cocaine Abstinence Based on Urine Toxicology Results | during last 3 weeks of the trial | Percentage of patients cocaine abstinent during last 3 weeks of the study (weeks 7-9) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Matched Placebo matched placebo
Placebo: matched placebo | 10 |
| Oral Micronized Progesterone Oral micronized progesterone (up to 400 mg/day)
Oral micronized progesterone: Oral micronized progesterone (up to 400 mg/day), suspended in olive oil | 11 |
| Total | 21 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 3 | 3 |
Baseline characteristics
| Characteristic | Oral Micronized Progesterone | Matched Placebo | Total |
|---|---|---|---|
| Age, Continuous | 45 years STANDARD_DEVIATION 8 | 41 years STANDARD_DEVIATION 9 | 43 years STANDARD_DEVIATION 8 |
| Race/Ethnicity, Customized Black | 5 participants | 4 participants | 9 participants |
| Race/Ethnicity, Customized Hispanic | 2 participants | 1 participants | 3 participants |
| Race/Ethnicity, Customized White, non-Hispanic | 4 participants | 5 participants | 9 participants |
| Region of Enrollment United States | 11 participants | 10 participants | 21 participants |
| Sex: Female, Male Female | 11 Participants | 10 Participants | 21 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 8 / 10 | 9 / 11 |
| serious Total, serious adverse events | 0 / 10 | 1 / 11 |
Outcome results
Primary
Cocaine Abstinence Based on Urine Toxicology Results
Percentage of patients cocaine abstinent during last 3 weeks of the study (weeks 7-9)
Time frame: during last 3 weeks of the trial
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Matched Placebo | Cocaine Abstinence Based on Urine Toxicology Results | 1 participants |
| Oral Micronized Progesterone | Cocaine Abstinence Based on Urine Toxicology Results | 3 participants |
p-value: <0.05Fisher Exact